Literature DB >> 7121522

Human leukocyte interferon and cimetidine for metastatic melanoma.

S Borgström, F E von Eyben, P Flodgren, B Axelsson, H O Sjögren.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7121522     DOI： 10.1056/nejm198210213071716

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

1.  A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer.

Authors:  K Sriskandan; P Garner; J Watkinson; K W Pettingale; D Brinkley; F M Calman; D E Tee
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

2.  The role of histamine antagonists on the development of experimental cancer in the rat.

Authors:  J Nee; N O'Higgins; D H Osborne; S Purdy
Journal:  Ir J Med Sci       Date:  1984-10       Impact factor: 1.568

3.  Comparison of the effects of three different treatment regimens of recombinant interferons (r-IFN alpha, r-IFN gamma, and r-IFN alpha + cimetidine) in disseminated malignant melanoma.

Authors:  A Steiner; C Wolf; H Pehamberger
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

4.  Role of recombinant interferon alpha 2 and cimetidine in patients with advanced malignant melanoma.

Authors:  T I Mughal; W A Robinson; M R Thomas; R Spiegel
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

5.  Lack of response in nine patients with breast cancer treated with fibroblast interferon.

Authors:  U Bruntsch; G Groos; F J Tigges; P H Hofschneider; W M Gallmeier
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

6.  Complete remission in a patient with acute myelogenous leukemia treated with leukocyte alpha-interferon and cimetidine.

Authors:  J Ankerst; R Fäldt; P G Nilsson; P Flodgren; H O Sjögren
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

7.  In vivo and in vitro anti-tumour activity of dimaprit.

Authors:  A Fray; C Burtin; P Scheinmann; G Lespinats; P Canu
Journal:  Agents Actions       Date:  1985-04

Review 8.  The interferons.

Authors:  J L Toy
Journal:  Clin Exp Immunol       Date:  1983-10       Impact factor: 4.330

Review 9.  Adverse reactions and interactions with H2-receptor antagonists.

Authors:  J Penston; K G Wormsley
Journal:  Med Toxicol       Date:  1986 May-Jun

Review 10.  Cimetidine as an immune response modifier.

Authors:  R Hast; P Bernell; M Hansson
Journal:  Med Oncol Tumor Pharmacother       Date:  1989
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.